Acelyrin (SLRN) News Today → How Biden has already won 2024 (From Porter & Company) (Ad) Free SLRN Stock Alerts $4.46 +0.21 (+4.94%) (As of 06/7/2024 08:52 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 8 at 3:59 PM | marketbeat.comSectoral Asset Management Inc. Buys Shares of 325,549 Acelyrin, Inc. (NASDAQ:SLRN)Sectoral Asset Management Inc. purchased a new stake in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 325,549 shares of the company's stock, valued at approxiJune 1, 2024 | marketbeat.comAcelyrin, Inc. (NASDAQ:SLRN) Sees Significant Decline in Short InterestAcelyrin, Inc. (NASDAQ:SLRN - Get Free Report) saw a significant drop in short interest during the month of May. As of May 15th, there was short interest totalling 7,020,000 shares, a drop of 17.7% from the April 30th total of 8,530,000 shares. Currently, 11.2% of the shares of the company are short sold. Based on an average daily volume of 1,160,000 shares, the days-to-cover ratio is presently 6.1 days.May 30, 2024 | marketbeat.comDecheng Capital LLC Purchases New Position in Acelyrin, Inc. (NASDAQ:SLRN)Decheng Capital LLC purchased a new stake in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 1,370,951 shares of the company's stock, valued at approximately $10,227,000. Acelyrin makes upMay 29, 2024 | globenewswire.comACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024May 24, 2024 | marketbeat.comQ2 2024 EPS Estimates for Acelyrin, Inc. (NASDAQ:SLRN) Increased by HC WainwrightAcelyrin, Inc. (NASDAQ:SLRN - Free Report) - Investment analysts at HC Wainwright raised their Q2 2024 earnings per share estimates for Acelyrin in a report released on Wednesday, May 22nd. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($0.33) per share for thMay 22, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) PT Raised to $18.00HC Wainwright boosted their price objective on shares of Acelyrin from $16.00 to $18.00 and gave the stock a "buy" rating in a research note on Wednesday.May 18, 2024 | finance.yahoo.comAcelyrin, Inc. (SLRN)May 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for ACELYRIN, INC. on Solid Financials and Promising PipelineMay 15, 2024 | investorplace.comSLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024May 15, 2024 | markets.businessinsider.comACELYRIN, INC.: Strong Buy Recommendation on Promising Izo Drug Prospects and Strategic AdvancementsMay 9, 2024 | marketwatch.comAcelyrin Founder Steps Down as CEOMay 9, 2024 | msn.comAcelyrin names Mina Kim as new Chief Executive OfficerMay 9, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Price Target Cut to $18.00HC Wainwright dropped their price objective on Acelyrin from $28.00 to $18.00 and set a "buy" rating for the company in a report on Thursday.May 9, 2024 | finance.yahoo.comACELYRIN, INC. Announces Leadership TransitionMay 9, 2024 | globenewswire.comACELYRIN, INC. Provides Business Update and Highlights Key Upcoming MilestonesMay 6, 2024 | marketbeat.comAcelyrin (SLRN) to Release Earnings on MondayAcelyrin (NASDAQ:SLRN) will be releasing earnings after the market closes on Monday, May 13, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=591359)April 29, 2024 | globenewswire.comACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024April 19, 2024 | marketbeat.comVontobel Holding Ltd. Purchases Shares of 325,549 Acelyrin, Inc. (NASDAQ:SLRN)Vontobel Holding Ltd. acquired a new position in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 325,549 shares of the company's stock, valued at approximately $2,429,000. Vontobel Holding Ltd. owned about 0.3April 17, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Hits New 12-Month Low at $5.10Acelyrin (NASDAQ:SLRN) Sets New 1-Year Low at $5.10April 16, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Shares Down 5.1% Acelyrin (NASDAQ:SLRN) Trading Down 5.1%April 14, 2024 | marketbeat.comAcelyrin, Inc. (NASDAQ:SLRN) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Acelyrin, Inc. (NASDAQ:SLRN - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven research firms that are covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating and four have given a buyApril 10, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Hits New 12-Month Low at $5.61Acelyrin (NASDAQ:SLRN) Sets New 12-Month Low at $5.61April 3, 2024 | marketbeat.comAcelyrin, Inc. Forecasted to Earn Q2 2024 Earnings of ($0.82) Per Share (NASDAQ:SLRN)Acelyrin, Inc. (NASDAQ:SLRN - Free Report) - Research analysts at HC Wainwright issued their Q2 2024 EPS estimates for shares of Acelyrin in a research report issued on Monday, April 1st. HC Wainwright analyst E. Bodnar expects that the company will earn ($0.82) per share for the quarter. HC WainApril 2, 2024 | marketbeat.comResearch Analysts Issue Forecasts for Acelyrin, Inc.'s Q1 2024 Earnings (NASDAQ:SLRN)Acelyrin, Inc. (NASDAQ:SLRN - Free Report) - HC Wainwright issued their Q1 2024 EPS estimates for shares of Acelyrin in a report issued on Monday, April 1st. HC Wainwright analyst E. Bodnar expects that the company will post earnings of ($0.86) per share for the quarter. HC Wainwright currentlyApril 1, 2024 | msn.comStocks Pressured as Bond Yields Jump on Strength in US ManufacturingApril 1, 2024 | markets.businessinsider.comACELYRIN, INC.: Promising Clinical Trials and Market Opportunity Justify Buy RatingApril 1, 2024 | marketbeat.comAcelyrin's (SLRN) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $28.00 target price on shares of Acelyrin in a research note on Monday.March 28, 2024 | investorplace.comSLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023March 28, 2024 | finance.yahoo.comACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent HighlightsMarch 28, 2024 | globenewswire.comACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent HighlightsMarch 21, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Shares Down 6.3% Acelyrin (NASDAQ:SLRN) Stock Price Down 6.3%March 21, 2024 | marketbeat.comWells Fargo & Company Raises Acelyrin (NASDAQ:SLRN) Price Target to $13.00Wells Fargo & Company raised their price objective on shares of Acelyrin from $11.00 to $13.00 and gave the stock an "equal weight" rating in a report on Thursday.March 20, 2024 | markets.businessinsider.comBuy Rating on ACELYRIN, INC.: Promising Clinical Prospects for Novel TED Therapy LonigutamabMarch 20, 2024 | markets.businessinsider.comAcelyrin Announces Positive Phase 1/2 Data For Lonigutamab In Thyroid Eye Disease; Stock UpMarch 20, 2024 | msn.comInvestors Cheer Acelyrin's Stock, Its Second Lead Candidate Shows Clinical Benefit In Thyroid Eye Disease PatientsMarch 20, 2024 | finance.yahoo.comACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye DiseaseMarch 20, 2024 | marketbeat.comAcelyrin, Inc. (NASDAQ:SLRN) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of Acelyrin, Inc. (NASDAQ:SLRN - Get Free Report) have earned an average rating of "Moderate Buy" from the seven research firms that are covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendatMarch 20, 2024 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Acelyrin (NASDAQ:SLRN)HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of Acelyrin in a research report on Wednesday.March 18, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Shares Gap Down to $7.84Acelyrin (NASDAQ:SLRN) Shares Gap Down to $7.84March 18, 2024 | finance.yahoo.comSLRN Apr 2024 2.500 putMarch 15, 2024 | marketbeat.comWalleye Capital LLC Acquires New Stake in Acelyrin, Inc. (NASDAQ:SLRN)Walleye Capital LLC acquired a new stake in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 447,355 shares of the company's stock, valued at approximately $4,550,000. Walleye Capital LLC owned approximately 0March 12, 2024 | seekingalpha.comAcelyrin: Analyzing Its Recovery And Potential In Psoriatic ArthritisMarch 12, 2024 | markets.businessinsider.comHold Rating Affirmed for ACELYRIN, INC. as Izokibep Faces Competitive Hurdles and Safety ConcernsMarch 12, 2024 | marketbeat.comAdage Capital Partners GP L.L.C. Sells 270,000 Shares of Acelyrin, Inc. (NASDAQ:SLRN)Adage Capital Partners GP L.L.C. lessened its holdings in shares of Acelyrin, Inc. (NASDAQ:SLRN - Free Report) by 73.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 100,000 shares of the company's stMarch 11, 2024 | marketwatch.comAcelyrin Stock Climbs 10% on Positive Results for Arthritis TreatmentMarch 11, 2024 | msn.comAcelyrin's Lead Drug Candidate Hits Primary Goal In Late-Stage Psoriatic Arthritis StudyMarch 11, 2024 | markets.businessinsider.comAcelyrin's Phase2b/3 Trial Of Izokibep In Psoriatic Arthritis Meets Primary EndpointMarch 11, 2024 | globenewswire.comACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic ArthritisMarch 11, 2024 | globenewswire.comACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for PatientsMarch 8, 2024 | marketbeat.comSchonfeld Strategic Advisors LLC Acquires 147,454 Shares of Acelyrin, Inc. (NASDAQ:SLRN)Schonfeld Strategic Advisors LLC increased its holdings in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) by 267.1% in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 202,662 shares of the company's stock after buying an additional 147,454 shares dur Get Acelyrin News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRN and its competitors with MarketBeat's FREE daily newsletter. Email Address It's time to ween off Chinese lithium! (Ad)As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promising companies to be watching closely Learn how this American company is leading the lithium-ion revolution SLRN Media Mentions By Week SLRN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SLRN News Sentiment▼1.880.77▲Average Medical News Sentiment SLRN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SLRN Articles This Week▼13▲SLRN Articles Average Week Get Acelyrin News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: KURA News SNDX News EWTX News TARO News DVAX News ARDX News MORF News SUPN News LGND News AKRO News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SLRN) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredYou won't believe what Citigroup just did to it's depositorsThe FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st...American Alternative | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored